Suppr超能文献

度洛西汀治疗重性抑郁和其他精神障碍。

Duloxetine in the treatment of major depression and other psychiatric disorders.

机构信息

Associate Professor of Clinical Psychiatry, Columbia University, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 69, New York, NY 10032, USA.

出版信息

Expert Rev Clin Pharmacol. 2008 Mar;1(2):195-205. doi: 10.1586/17512433.1.2.195.

Abstract

Duloxetine is a new antidepressant agent approved for use in major depressive disorder, generalized anxiety disorder and diabetic peripheral neuropathic pain. It potently inhibits the reuptake of serotonin and norepinephrine in the synaptic cleft. This dual mechanism of action is thought to provide a favorable pharmacological profile with regards to efficacy, onset of action and analgesic properties. Pilot studies on the efficacy of duloxetine in the treatment of dysthymia and other psychiatric disorders have also shown promising results. Duloxetine appears well tolerated and its safety profile is similar to that of the selective serotonin-reuptake inhibitors.

摘要

度洛西汀是一种新型抗抑郁药,已获准用于治疗重度抑郁症、广泛性焦虑症和糖尿病周围神经性疼痛。它能强力抑制突触间隙中 5-羟色胺和去甲肾上腺素的再摄取。这种双重作用机制被认为在疗效、作用开始和镇痛特性方面提供了有利的药理学特征。关于度洛西汀治疗恶劣心境和其他精神障碍的疗效的初步研究也显示出有希望的结果。度洛西汀的耐受性良好,其安全性与选择性 5-羟色胺再摄取抑制剂相似。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验